Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 6/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | PKM | P14618 | 1/20 | 0.46 |
| ▸ | RORC | P51449 | 11/20 | 0.41 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25109828 | 0.96 | HRH3 (0.48) | HRH3KDM4EALDH1A1MAPTPKM | |
| SCHEMBL25108947 | 0.93 | HRH3 (0.47) | HRH3KDM4EALDH1A1MAPTPKM | |
| SCHEMBL25109781 | 0.89 | HRH3 (0.48) | HRH3KDM4EALDH1A1MAPTPKM | |
| SCHEMBL24513988 | 0.88 | HRH3 (0.57) | HRH3KDM4EALDH1A1MAPTPKM | |
| SCHEMBL22794555 | 0.87 | HRH3 (0.56) | HRH3KDM4EALDH1A1MAPTPKM | |
| SCHEMBL25468369 | 0.87 | HRH3 (0.46) | HRH3KDM4EALDH1A1MAPTPKM | |
| SCHEMBL22794340 | 0.87 | HRH3 (0.61) | HRH3KDM4EALDH1A1MAPTPKM | |
| SCHEMBL25468377 | 0.86 | HRH3 (0.45) | HRH3KDM4EALDH1A1MAPTPKM | |
| SCHEMBL25481249 | 0.84 | HRH3 (0.39) | HRH3RORCKCNH2 | |
| SCHEMBL22795033 | 0.84 | HRH3 (0.46) | HRH3KDM4EALDH1A1MAPTPKM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230149549-A1 | SMARCA DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2023-05-18 | — | — | US | disclosed |
| US-20230072658-A1 | SMARCA DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2023-03-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230149549-A1 | SMARCA DEGRADERS AND USES THEREOF | SMARCA1, SMARCB1, SMARCE1 | HRH3 1734/4885KDM4E 613/4885ALDH1A1 3473/4885 |
| US-20230072658-A1 | SMARCA DEGRADERS AND USES THEREOF | SMARCA1, SMARCB1, SMARCE1 | HRH3 1490/4885KDM4E 624/4885ALDH1A1 3736/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.